Introduction
============

Acute kidney injury (AKI) is a serious complication of critical illness that is associated with substantial morbidity and mortality \[[@B1]-[@B7]\]. Extracorporeal renal replacement therapy (RRT) has long been used as supportive treatment of AKI, and has traditionally focused on averting the life-threatening derangements associated with kidney failure (that is, metabolic acidosis, hyperkalemia, uremia, and/or fluid overload) while allowing time for organ recovery. Observations from a large multinational, multicenter survey found the prevalence of severe AKI supported with RRT in critically ill patients was approximately 6% \[[@B7]\].

A critical decision in the support of critically ill patients with AKI is when to initiate RRT. Data have emerged to suggest that earlier RRT initiation may attenuate kidney-specific and non-kidney organ injury from acidemia, uremia, fluid overload, and systemic inflammation \[[@B8],[@B9]\]. This in turn, may potentially translate into improved survival and earlier recovery of kidney function \[[@B9]\]. Unfortunately, in the absence of refractory acidemia, toxic hyperkalemia and intravascular fluid overload contributing to respiratory failure, there is limited evidence to guide clinicians on when to initiate RRT in critically ill patients with AKI. The question of timing of initiation of RRT (that is, \"early\" versus \"late\") has seldom been the focus of high-quality or rigorous evaluation \[[@B10]-[@B23]\]. As a consequence, initiatives aimed at identifying the \"optimal timing of initiation of RRT\" in AKI have been given the highest priority for investigation by the Acute Kidney Injury Network (AKIN) \[[@B24],[@B25]\].

Accordingly, we conducted a systematic review and meta-analysis to determine whether \"early\" versus \"late\" initiation of RRT in critically ill patients with AKI is associated with a survival benefit or more favourable renal recovery.

Materials and methods
=====================

This study was conducted and reported according to PRISMA guidelines \[[@B26]\] (Additional File [1](#S1){ref-type="supplementary-material"}).

Search strategy
---------------

We performed a comprehensive search of MEDLINE (1985 to July 2010), PubMed, EMBASE (1985 to July 2010), the Cochrane Central Registry of Controlled Trials, Web of Science, and Scopus to identify randomised trials and cohort studies that assessed the timing of initiation of RRT in critically ill patients with AKI. We restricted our search to clinical studies performed in adult populations and published in the English language. We also excluded studies published prior to 1985 largely to reflect important advances in RRT technology and in critical care support not available in older studies.

We extended our search to include clinical trial registries (Controlled trials *meta*Register) and review of abstracts from selected scientific proceedings (Society of Critical Care Medicine, European Society of Intensive Care Medicine and American Society of Nephrology). The bibliographies of all retrieved articles were also hand-searched.

Our search was based on four search themes using the Boolean operator \'OR\' (Additional File [2](#S2){ref-type="supplementary-material"}). The first Boolean heading included keyword/MESH headings describing RRT and its different modalities. The second Boolean heading employed terms describing AKI. The third Boolean heading combined the keywords/MESH headings related to critical illness and its different populations. The fourth Boolean search included terms describing timing or initiation of therapy. The searches were combined by using the Boolean term \"AND\".

Study selection
---------------

Two reviewers (CK and MF/IS/SM) independently performed an initial eligibility screen of all retrieved titles and abstracts (when available). Those studies reporting original data that specifically mentioned the application of RRT in patients with AKI were selected for further review. Full-text review was independently performed by two reviewers (as above) for the following specific eligibility criteria: 1) observational cohort and/or randomised/quasi-randomised clinical trial (RCT) design; 2) adult critically ill population; 3) diagnosis of AKI; 4) description of factors related to timing of initiation of RRT; and 5) description of mortality and/or clinically relevant secondary outcomes (that is, kidney recovery and/or dialysis independence, duration of RRT, and ICU length of stay).

Disagreements between reviewers were resolved by a third reviewer or by discussion and consensus.

Data extraction
---------------

All data were extracted independently with standardised forms with subsequent discussion of any discrepancies. Data were collected on study characteristics and quality, demographics and baseline characteristics (that is, clinical/biochemical parameters at initiation of RRT), and details of RRT modality (that is, continuous venovenous hemofiltration (CVVH), continuous venovenous hemodialysis (CVVHD), continuous venovenous hemodiafiltration (CVVHDF), and intermittent hemodialysis (IHD)). The primary outcome measure was mortality. Secondary outcomes included: kidney recovery and/or dialysis independence, duration of RRT and ICU length of stay.

Assessment of methodological quality
------------------------------------

Randomised studies were appraised using a modified version of the Jadad score \[[@B27]\]. Evaluation of cohort studies was done in a descriptive fashion similar to previous studies \[[@B28]\], incorporating the reported criteria for RRT initiation, assembly of control groups, comparability of intervention/control arms (that is, baseline characteristics, severity of illness, dialysis modality), and a description of dropouts.

Data analysis and assessment for bias
-------------------------------------

Data were analysed by STATA version 11 (StataCorp, College Station, TX. USA) and Comprehensive Meta-analysis version 2 (Biostat Inc., Englewood, NJ, USA) \[[@B29]\]. We assessed and quantified statistical heterogeneity for each pooled summary estimate using Cochran\'s Q statistic and the *I*^*2*^statistic, respectively \[[@B30]\]. Pooled analysis was performed using the DerSimonian and Laird random effects model and reported as OR with 95% CIs. Meta-regression analysis was performed to assess for possible sources of heterogeneity according to the following pre-defined variables: criteria used to initiate RRT (that is, creatinine, urea, or other), severity of illness (Acute Physiology and Chronic Health (APACHE II) score), type of critical care unit (mixed medical/surgical vs. surgical alone), and study design (observational vs. RCT). Publication bias was assessed using Egger\'s regression model, and visualised with a funnel plot \[[@B31]\].

Results
=======

Trial selection
---------------

A total of 1,494 citations were identified (Figure [1](#F1){ref-type="fig"}). After primary and secondary screen, 15 studies fulfilled all criteria for final analysis (13 articles and 2 abstracts).

![**Outline of study selection process**.](cc10061-1){#F1}

Trial characteristics
---------------------

We found two randomised trials \[[@B10],[@B32]\], four prospective cohort studies \[[@B21],[@B33]-[@B35]\], and nine retrospective cohort studies \[[@B13],[@B15],[@B36]-[@B42]\]. Of these, 13 were published as articles in peer-reviewed journals and 2 studies were published as abstracts only \[[@B33],[@B35]\]. Eight studies examined only patients with surgical diagnoses (that is, cardiac, abdominal, and trauma) while the remaining seven studies were from mixed medical/surgical ICUs.

Assessment of trial quality
---------------------------

Of the two included RCTs, one fulfilled all quality indicators \[[@B10]\] (Table [1](#T1){ref-type="table"}), whereas the other did not describe the methods of randomisation or perform analysis by intention to treat \[[@B32]\]. Of the 13 cohort studies, none fulfilled all quality indicators (Table [2](#T2){ref-type="table"}). Only five had a prospectively assembled control group \[[@B21],[@B33]-[@B35],[@B41]\], four had comparable modes of RRT between the early and late initiation groups \[[@B15],[@B38],[@B39],[@B41]\], and only three studies accounted for withdrawals/loss to follow-up \[[@B34],[@B35],[@B38]\].

###### 

Summary of quality indicators and validity assessment of randomised trials fulfilling inclusion criteria

  Randomised control trials                                                                                                    **Bouman**\[[@B10]\]   **Sugahara**\[[@B32]\]
  ---------------------------------------------------------------------------------------------------------------------------- ---------------------- ------------------------
  Was the study described as randomised?                                                                                       Yes                    Yes
  Was the method used to randomise described and appropriate (table of random numbers, computer generated, and so on)?         Yes                    No
  Was there a description of withdrawals and dropouts?                                                                         Yes                    Yes
  Was there intention to treat analysis?                                                                                       Yes                    No
  Were control and intervention group comparable with respect to disease type and demographics?                                Yes                    No
  Were the control and intervention groups comparable with respect to disease severity?                                        Yes                    Yes
  Was dialysis type comparable between groups in terms of dose, solution used, filtration vs dialysis, and type of membrane?   Yes                    Yes

###### 

Summary of quality indicators of non-randomised studies fulfilling inclusion criteria

  Observational Study                                                                                                              **Sabater**\[[@B33]\]   **Bagshaw**\[[@B34]\]   **Gettings**\[[@B15]\]   **Elahi**\[[@B38]\]   **Demirkilic**\[[@B13]\]   **Liu**\[[@B21]\]   **Andrade**\[[@B36]\]   **Wu**\[[@B42]\]   **Manche**\[[@B40]\]   **Iyem**\[[@B39]\]   **Shiao**\[[@B41]\]   **Carl**\[[@B37]\]   **Bagshaw**\[[@B35]\]
  -------------------------------------------------------------------------------------------------------------------------------- ----------------------- ----------------------- ------------------------ --------------------- -------------------------- ------------------- ----------------------- ------------------ ---------------------- -------------------- --------------------- -------------------- -----------------------
  **Were criteria for initiation of RRT clearly defined in each group?**                                                           Yes                     Yes                     Yes                      Yes                   Yes                        Yes                 No                      Yes                No                     Yes                  Yes                   Yes                  Yes
  **Was the measurement of criterion (or lab value) for initiation of RRT reliable?**                                              Yes                     Yes                     Yes                      Yes                   Yes                        Yes                 No                      Yes                No                     No                   Yes                   Yes                  Yes
  **Was control group prospectively assembled? (vs historical, or case-control)**                                                  Yes                     Yes                     No                       No                    No                         Yes                 No                      No                 No                     No                   Yes                   No                   Yes
  **Were control and intervention group comparable with respect to disease type and demographics?**                                No                      No                      Yes                      Yes                   Yes                        Yes                 Yes                     Yes                Yes                    Yes                  Yes                   Yes                  Yes
  **Were the control and intervention group comparable with respect to disease severity?**                                         No                      No                      Yes                      Yes                   Yes                        No                  Yes                     Yes                No                     Yes                  Yes                   Yes                  Yes
  **Was dialysis type comparable between groups in terms of dose, solution used, filtration vs dialysis, and type of membrane?**   No                      No                      Yes                      Yes                   No                         No                  No                      No                 No                     Yes                  Yes                   No                   No
  **Was there a description of withdrawals and dropouts?**                                                                         No                      Yes                     No                       Yes                   No                         No                  No                      No                 No                     No                   No                    No                   Yes

Type of renal replacement therapy and criteria used for
-------------------------------------------------------

Continuous renal replacement therapy (CRRT) was used as the principle modality for RRT in eight studies \[[@B10],[@B13],[@B15],[@B32],[@B33],[@B38],[@B39],[@B41]\], while a combination of IHD and CRRT were used in the remaining studies \[[@B21],[@B34]-[@B37],[@B40],[@B42]\] (Table [3](#T3){ref-type="table"}). Six studies defined timing of initiation of RRT based on cut-offs in serum urea \[[@B15],[@B21],[@B34],[@B35],[@B37],[@B42]\], two studies based on cut-offs in serum creatinine \[[@B33],[@B41]\], one study based on the Risk, Injury, Failure, Loss, End-stage (RIFLE) criteria \[[@B3]\], and four based on urine output \[[@B10],[@B32],[@B38],[@B40]\]. Three other studies used a composite of factors to designate early initiation \[[@B13],[@B36],[@B39]\]. Eight studies reported duration of RRT \[[@B10],[@B13],[@B15],[@B33],[@B34],[@B38]-[@B40]\] (range 1 to 20 days). Seven studies described recovery of kidney function (RRT independence) \[[@B10],[@B15],[@B32],[@B34],[@B35],[@B39],[@B41]\].

###### 

Characteristics of studies included in meta-analysis

  **Author**:                 Year   Study design           Population                Modality          Early (n)   Late (n)   Early criteria                                   Late criteria
  --------------------------- ------ ---------------------- ------------------------- ----------------- ----------- ---------- ------------------------------------------------ ------------------------------------
  **Bouman**\[[@B10]\]        2002   Randomised             Cardiac surgery/medical   CVVH              35          36         RRT within 12 hours if Urine Output \<30 ml/hr   Urea \>40 mmol/l or K \>6.5 mmol/L
  **Sugahara**\[[@B32]\]      2004   Randomised             Cardiac Surgery           CVVH              14          14         Urine Output \<20 ml/hr                          Urine Output \<30 cc/hr
  **Liu**\[[@B21]\]           2006   Prospective Cohort     Medical,Surgery           CRRT/IHD          122         121        Urea \<27.1 mmol/L                               Urea \>27.1 mmol/L
  **Sabater**\[[@B33]\]       2008   Prospective Cohort     Medical (Septic Shock)    CVVHF             9           23         Rifle Criteria (Risk, Injury)\*                  Rifle Criteria (Failure)\*\*
  **Bagshaw**\[[@B34]\]       2009   Prospective Cohort     Medical, Surgical         CRRT/IHD          618         619        Urea \<24.2 mmol/L                               Urea \>24.2 mmol/L
  **Bagshaw**\[[@B35]\]       2010   Prospective Cohort     Medical, Surgical         CRRT/IHD          117         117        Urea \<23 mmol/L                                 Urea \>23 mmol/L
  **Gettings**\[[@B15]\]      1999   Retrospective Cohort   Trauma                    CAVHD and CVVHD   41          59         Urea \<21.4 mmol/L                               Urea \>21.4 mmol/L
  **Elahi**\[[@B38]\]         2004   Retrospective Cohort   Cardiac surgery           CVVH              28          36         Urine Output \<100 cc in 8 hrs                   K \>6 mmol/L, Cr \>250 mmol/L
  **Dermirkilic**\[[@B13]\]   2004   Retrospective Cohort   Cardiac Surgery           CVVHDF            27          34         Cr \>400 μmol/L, Potassium \>5.5 mmol/L          Oliguria
  **Andrade**\[[@B36]\]       2007   Retrospective Cohort   Medical (ARDS/Sepsis)     IHD/SLED          18          15         On admission                                     At 24 hours
  **Wu**\[[@B42]\]            2007   Retrospective Cohort   Surgical ALF              IHD/CVVH          54          26         Urea \< 28.6 mmol/L                              Urea \>28.6 mmol/L
  **Manche**\[[@B40]\]        2008   Retrospective Cohort   Cardiac Surgery           IHD               56          15         Hyperkalemia                                     U/O \<0.5 ml/kg/hour
  **Iyem**\[[@B39]\]          2009   Retrospective Cohort   Cardia Surgery            CVVH              95          90         RRT on admission                                 After 48 hours when anuric
  **Shiao**\[[@B41]\]         2009   Retrospective Cohort   Surgery/Trauma            CVVH              51          47         Rifle Criteria (Risk)\*                          Rifle Injury, Failure\*\*
  **Carl**\[[@B37]\]          2010   Retrospective Cohort   Medical (sepsis)          CRRT/IHD          85          62         Urea \<35.7 mmol/l                               Urea \>35.7 mmol/L

Abbreviations: Cr = creatinine (μmol/L); K = potassium (mmol/L).

RIFLE Criteria Risk: Increase in serum Creatinine by 1.5 times or urine output \<0.5 ml/kg/hour × 6 hours.

RIFLE Criteria Injury: Increase in serum Creatinine by 2 times or urine output \<0.5 ml/kg/hour × 12.

RIFLE Criteria Failure: Increase in serum Creatinine by 3 times or urine output \<0.3 ml/kg/hour × 24.

Mortality
---------

The OR for 28-day mortality is shown in Figure [2](#F2){ref-type="fig"}. Overall 28-day mortality across the 15 trials was 53.3% (1,431/2,684). Early RRT initiation was associated with reduced mortality compared to late initiation (pooled OR 0.45; 95% CI, 0.28 to 0.72, *P*\< 0.001). However, there was significant statistical heterogeneity (*I*^*2*^*= 78%, Q 63.7)*.

![**Forest plot of all 15 studies (Random Effects Model, OR, 95% CI)**.](cc10061-2){#F2}

Subgroup analysis was performed according to type of ICU (mixed vs. surgery only; Figure [3](#F3){ref-type="fig"}). The overall effect estimate of the surgical group (OR 0.31, 95% CI 0.16 to 0.58, *n*= 8) was not statistically different than that of the mixed group (OR 0.71, 95% CI 0.40 to 1.24, *n*= 7) with a *P*-value of 0.06. There was also no statistical difference in the overall effect estimates between prospective and retrospective studies. There was also no statistically significant effect on the pooled OR for mortality when analysed according to baseline APACHE II scores, creatinine, and urea levels. Therefore, meta-regression analyses with these variables could not account for the large amounts of heterogeneity observed.

![**Forest plot stratified for surgery only (*n*= 8) vs. Medical (mixed, *n*= 7)**.](cc10061-3){#F3}

Secondary outcomes
------------------

Five studies \[[@B15],[@B32],[@B34],[@B39],[@B41]\] (of seven reporting data) described a higher rate of kidney recovery to dialysis independence at hospital discharge for patients receiving early RRT (Table [4](#T4){ref-type="table"}). Pooled analysis of these seven studies showed a non-significant summary estimate favouring early RRT (OR 0.62, 95% CI 0.34 to 1.13, I^2^= 69.6%; Figure [4](#F4){ref-type="fig"}).

###### 

Baseline characteristics and outcomes in intervention and control groups in 14 studies included in meta-analysis

  **Author**:                 Year   Creatinine\*   Urea\*      APACHE II score   Dialysis-Free (%)   Duration of RRT (days)   ICU Length of Stay (days)   Mortality at 28-days (%)                                                                
  --------------------------- ------ -------------- ----------- ----------------- ------------------- ------------------------ --------------------------- -------------------------- ---- ---------- ---------- ----------- ----------- --------- ---------
  **Bouman**\[[@B10]\]        2002   5 (4)\*\*      6 (4)\*\*   NR                NR                  21.7(5.5)                23.6(8.3)                   17                         22   5.7        6.6        NR          NR          11/35     9/36
  **Sugahara**\[[@B32]\]      2004   256            265         NR                NR                  19(2)                    18(3)                       10                         2    NR         NR         NR          NR          2/14      12/14
  **Liu**\[[@B21]\]           2006   301            415         16.9              41.0                NR                       NR                          NR                         NR   NR         NR         NR          NR          43/122    50/121
  **Sabater**\[[@B33]\]       2008   NR             NR          NR                NR                  24(8)                    29(9)                       NR                         NR   6          7          NR          NR          1/9       16/23
  **Bagshaw**\[[@B34]\]       2009   230            396         15.0 (5.4)        38.8 (12)           11.1 (3)^§^              10.7 (3)^§^                 91                         74   4 (2-13)   6 (2-15)   13 (7-24)   13 (6-28)   392/618   380/619
  **Bagshaw**\[[@B35]\]       2010   273            489         13.5              38.0                31(9.3)                  28.1(6.7)                   22                         30   NR         NR         12          14          67/117    54/117
  **Gettings**\[[@B15]\]      1999   148            238         15.2 (4.6)        33.7 (10)           NR                       NR                          16                         11   17.7       20.2       NR          NR          25/41     47/59
  **Elahi**\[[@B38]\]         2004   328            379         23.9 (12)         26.8 (22)           NR                       NR                          NR                         NR   4.61       4.57       8.5         12.5        8/28      12/36
  **Dermirkilic**\[[@B13]\]   2004   NR             NR          NR                NR                  NR                       NR                          NR                         NR   4.32       4.56       7.8         12.4        8/27      15/34
  **Andrade**\[[@B36]\]       2007   583            548         73.9 (6.6)        82.8 (6.9)          24.5 (1.4)               26 (1.2)                    NR                         NR   NR         NR         20          13.6        3/18      10/15
  **Wu**\[[@B42]\]            2007   256            415         16.5 (7)          42.4 (12)           18.2 (5.1)               20.5 (5.3)                  NR                         NR   NR         NR         NR          NR          34/54     22/26
  **Manche**\[[@B40]\]        2008   233            404         14.4 (3.1)        35.2 (18)           NR                       .                           NR                         NR   1.8        6.5        NR          NR          14/56     13/15
  **Iyem**\[[@B39]\]          2009   186            256         19.5 (2.7)        24.3 (1.9)          NR                       .                           95                         87   1.6        4.1        2           4           5/95      6/90
  **Shiao**\[[@B41]\]         2009   292            336         24.6 (14)         29.2 (14)           18.2 (5.4)               18.8 (6.3)                  21                         10   NR         NR         NR          NR          22/51     35/47
  **Carl**\[[@B37]\]          2010   442            514         23.6 (7.2)        48.9 (10)           24.8 (6.2)               24.7 (6.1)                  NR                         NR   NR         NR         27          39.1        44/85     42/62

\* Continuous variables reported as means and standard deviations when given.

\*\* Bouman *et al*. reported creatinine clearance (ml/minute).

![**Forest plot of seven studies reported RRT independence (OR, 95% CI)**.](cc10061-4){#F4}

Due to the variability in the reporting of the remaining secondary outcomes of interest and evidence of significant statistical heterogeneity, we did not perform a pooled analysis for RRT duration or ICU length of stay. Rather, we present the data on these secondary outcomes descriptively (Table [4](#T4){ref-type="table"}). Seven studies \[[@B10],[@B13],[@B15],[@B33],[@B34],[@B39],[@B40]\] (of eight reported data) described shorter duration of RRT in those receiving early RRT. Five studies \[[@B13],[@B35],[@B37]-[@B39]\] (of six reported data) described a reduction in ICU length of stay in those receiving early RRT.

Publication bias
----------------

We assessed for publication bias using Egger\'s linear regression test and found statistical evidence of bias (beta-coefficient of the bias estimate = -3.19, 95% CI = -4.58 to -1.81, *P*= 0.0003). There appears to be publication bias towards smaller studies reporting positive results (that is, mortality benefit associated with early initiation of RRT) (Figure [5](#F5){ref-type="fig"}).

![**Funnel plot of all 15 studies**. X-axis is log of risk ratio of death. Y-axis is Standard error of Log Risk ratio of death. Egger\'s regression (plot not shown): Bias (intercept) -3.19736, *P*-value = 0.00025 (null hypothesis stating no small study effects is REJECTED).](cc10061-5){#F5}

Discussion
==========

This systematic review and meta-analysis of 15 unique studies compared \"early\" versus \"late\" initiation of RRT in critically ill patients with AKI and suggests that earlier initiation is associated with improved survival. There is insufficient evidence to conclude that kidney recovery to dialysis independence is influenced by the timing of RRT initiation.

To our knowledge, this is the first systematic review to address the question of whether timing of RRT initiation has an important impact on survival and kidney recovery in the critically ill. Previous work on this issue was not specifically focused on critically ill patients supported in an ICU environment \[[@B43]\]. Moreover, in contrast to previous work \[[@B43]\], we intentionally excluded older studies (that is, published before 1985) due to the considerable advances in available technology for providing RRT, the marked demographic transition critically ill populations (that is, older, more comorbid illness, receiving more complex procedures/interventions), and the evolution in general of interventions and technology available to support the critically ill. Accordingly, our systematic review is uniquely focused on how the timing of initiation of RRT impacts survival and kidney recovery in modern ICU practice. Despite these strengths, inferences from our study are limited for two important reasons. First, we found significant statistical heterogeneity. As such, we were unable to calculate effect sizes for all secondary outcomes of interest. We attribute the observed heterogeneity to marked variability between published studies in study design and quality, which we were unable to account for in sensitivity analyses. Second, we found evidence of publication bias towards smaller studies where early initiation of RRT was associated with a survival benefit. As a consequence, the magnitude of the pooled effect estimate may overstate the \`true\` benefit, if any, of early compared with late RRT initiation.

Our findings are broadly consistent with those reported previously \[[@B43]\]. However, our study more specifically focused on the critically ill and benefited from the recent publication of several additional studies. In a previous meta-analysis \[[@B43]\], Seabra and colleagues explored heterogeneity but found no association between effect estimate and date of publication, RRT modality, sample size, duration of study follow-up, and study quality. Likewise, we could not account for the observed heterogeneity by meta-regression according to patient and population characteristics including type of ICU, severity of illness (baseline APACHE II scores), and metabolic derangements (baseline creatinine and urea levels). Accordingly, the heterogeneity observed is most likely explained by differences in study design (that is, clinical trial vs. cohort study), operational definitions for RRT timing (that is, clinical vs. biochemical criteria) and the inability to account for heterogeneity in clinical practice patterns. Our study has several notable strengths compared to earlier work. First, we have included eight additional clinical studies \[[@B32]-[@B35],[@B37],[@B39]-[@B41]\]. Second, we excluded studies for which there was no comparable control group \[[@B44]-[@B46]\], as well as older studies that have no applicability to current ICU practice \[[@B11],[@B16],[@B22]\]. Third, we have found evidence of publication bias and explain how older reports from smaller studies favouring early RRT may have influenced our summary estimates.

The utilization of RRT in critically ill patients with AKI is relatively common \[[@B7],[@B47]\]. Importantly, the incidence is increasing \[[@B48]\]. These critically ill patients have a risk of death approaching 60% \[[@B2],[@B7]\]. The decision to initiate RRT is a modifiable intervention for these patients; however, it also represents a significant escalation in the complexity and cost of their support. The current uncertainty over the optimal time to initiate RRT is a critical knowledge gap in evidence that has almost certainly contributed to the wide variation in clinical practice. Moreover, this has been further compounded by a lack of consensus and a standardised definition for \"early\" RRT \[[@B24]\]. There are currently numerous clinical, biochemical, and physiological factors that are considered when deciding to initiate RRT; however, there remains no consensus guidelines or rigorous evidence to guide clinicians on this important issue \[[@B24]\]. This is analogous to the uncertainty regarding the optimal dose-intensity of RRT in critically ill patients with AKI that was largely settled by the recent publication of two large randomised trials \[[@B49],[@B50]\]. A future randomised trial will ideally require broad-based consensus on eligibility criteria and operational definitions for \'early\' and \'standard\' initiation of RRT in critically ill patients to ensure feasibility and adequate separation of treatment arms. In addition, such a study may benefit from the integration of novel kidney-injury specific biomarkers to aid in the prediction of those who will develop worsening AKI. Understanding methods to further optimise the delivery of acute RRT for critically ill patients with AKI is of utmost importance to improve patient outcomes, guide resource utilization, and rationally deliver standardised care.

Conclusions
===========

In summary, our systematic review suggests that early institution of RRT in critically ill patients with AKI may have a measurable benefit on survival. However, existing evidence is based on mostly smaller studies with important differences in design and quality, and only two randomised trials. In the absence of novel evidence from a multi-centric suitably-designed randomised trial, conclusive treatment recommendations on the optimal time to initiate RRT remain uncertain. Future investigation must be targeted at defining acceptable \"early\" RRT criteria and determining whether \"early\" initiation of RRT, compared with the current standard-of-care, has an important modifying influence on short- and long-term survival and kidney recovery.

Key messages
============

• The overall design and quality of studies comparing early versus late initiation of RRT in critically ill patients with AKI is low.

• Earlier initiation of RRT in critically ill patients with AKI may have a beneficial impact on survival.

• A well-designed randomised trial targeting acceptable \'early\' compared with \"standard\" criteria for RRT initiation in homogenous patient populations is needed to definitively determine the effect of RRT timing on patient outcomes.
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